Last reviewed · How we verify
AP-101
AP-101 is a small molecule that targets the serotonin receptor.
AP-101 is a small molecule that targets the serotonin receptor. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | AP-101 |
|---|---|
| Sponsor | AL-S Pharma |
| Drug class | Serotonin receptor modulator |
| Target | 5-HT receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 2 |
Mechanism of action
It works by binding to the serotonin receptor, which helps to reduce symptoms of depression and anxiety. This is achieved through the modulation of serotonin levels in the brain.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer (PHASE2)
- A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS) (PHASE2)
- Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis (PHASE1)
- A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |